COVID-19 preclinical drug development database
Name: Douglas Thomson (CEO)
Email Address: firstname.lastname@example.org
Pneumagen has developed Neumifil, a mutlivalent sialic acid binding biologic, which we have shown protects mice from lethal doses of all influenza viruses tested (e.g. pandemic 2009 H1N1, avian H5N1, Shanghai H7N9). We have also shown antiviral activity against RSV in an animal model. PHE and Glasgow's CVR tested Neumifil, and other of our biologics, in vitro against SARS-CoV-2. Very significant antiviral activity was shown in both a preventative and a treatment assay. We are progressing towards first-in-human trials early next year.